MedPath

Astellas Pharma Global Development, Inc.

πŸ‡ΊπŸ‡ΈUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Phase 3
Active, not recruiting
Conditions
Urothelial Cancer
Interventions
First Posted Date
2020-01-10
Last Posted Date
2025-06-13
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
1030
Registration Number
NCT04223856
Locations
πŸ‡ΊπŸ‡Έ

Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States

πŸ‡ΊπŸ‡Έ

Arizona Oncology Associates PD - HOPE, Tucson, Arizona, United States

πŸ‡ΊπŸ‡Έ

Providence St Joseph Medical Center, Burbank, California, United States

and more 257 locations

A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Phase 1
Active, not recruiting
Conditions
Allergic to House Dust Mites
Interventions
Biological: Placebo
First Posted Date
2019-12-04
Last Posted Date
2025-04-24
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
28
Registration Number
NCT04184895
Locations
πŸ‡©πŸ‡ͺ

Site DE49001, Berlin, Germany

πŸ‡©πŸ‡ͺ

Site DE49002, Hannover, Germany

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Conditions
Locally Advanced or Metastatic Urothelial Carcinoma (UC)
First Posted Date
2019-10-23
Last Posted Date
2020-01-13
Lead Sponsor
Astellas Pharma Global Development, Inc.
Registration Number
NCT04136808
Locations
πŸ‡ΊπŸ‡Έ

UCLA Hematology Oncology, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

John Wayne Cancer Institute, Santa Monica, California, United States

πŸ‡ΊπŸ‡Έ

St. Joseph Heritage Medical Group, Santa Rosa, California, United States

and more 12 locations

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2019-09-19
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
17
Registration Number
NCT04096157
Locations
πŸ‡ΊπŸ‡Έ

Parexel International, Baltimore, Maryland, United States

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2019-09-19
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
24
Registration Number
NCT04094519
Locations
πŸ‡²πŸ‡©

Site MD37301, Chisinau, Moldova, Republic of

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Phase 1
Completed
Conditions
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome
Interventions
First Posted Date
2019-09-06
Last Posted Date
2024-11-26
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
43
Registration Number
NCT04079296
Locations
πŸ‡ΊπŸ‡Έ

City of Hope, Duarte, California, United States

πŸ‡ΊπŸ‡Έ

Memorial Healthcare System-West, Pembroke Pines, Florida, United States

πŸ‡ΊπŸ‡Έ

NYU Langone Health, New York, New York, United States

and more 13 locations

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2019-09-04
Last Posted Date
2024-10-23
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
97
Registration Number
NCT04077879
Locations
πŸ‡ΊπŸ‡Έ

California Clinical Trials Medical Group / Parexel, Glendale, California, United States

A Study to Assess ASP2713 in Healthy Subjects

Phase 1
Withdrawn
Conditions
Healthy Volunteers
Interventions
Drug: placebo
First Posted Date
2019-07-12
Last Posted Date
2024-10-16
Lead Sponsor
Astellas Pharma Global Development, Inc.
Registration Number
NCT04017208

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

Phase 3
Completed
Conditions
Hot Flashes
Interventions
Drug: placebo
First Posted Date
2019-07-01
Last Posted Date
2024-11-05
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
501
Registration Number
NCT04003142
Locations
πŸ‡ΊπŸ‡Έ

Mesa Obstetricians and Gynecologists, Mesa, Arizona, United States

πŸ‡ΊπŸ‡Έ

Precision Trials, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Visions Clinical Research - Tuscon, Tucson, Arizona, United States

and more 90 locations

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

Phase 3
Completed
Conditions
Hot Flashes
Interventions
Drug: placebo
First Posted Date
2019-07-01
Last Posted Date
2024-11-04
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
527
Registration Number
NCT04003155
Locations
πŸ‡ΊπŸ‡Έ

SEC Clinical Research, Andalusia, Alabama, United States

πŸ‡ΊπŸ‡Έ

Central Research Associates, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Achieve Clinical Research, LLC, Ensley, Alabama, United States

and more 88 locations
Β© Copyright 2025. All Rights Reserved by MedPath